Posts With Tag Cancer Therapies

Explore Karyopharm's latest quarterly results, revealing mixed financial performance, significant losses, and a hold recommendation. Key metrics include $145.2M revenue and $76.4M net loss.

Explore Renovaro Inc.'s Q4 2024 financial analysis, detailing significant losses, legal challenges, and capital strategies. Key insights for investors on holding positions.

Explore Sonnet BioTherapeutics Q4 2024 financial analysis, highlighting revenue, net loss, cash position, and future funding needs. Key insights for investors and market outlook.